vs
Claritev Corp（CTEV）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
Claritev Corp的季度营收约是REPLIGEN CORP的1.2倍（$246.6M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -32.7%，领先39.4%），REPLIGEN CORP同比增速更快（13.6% vs 6.2%），Claritev Corp自由现金流更多（$36.4M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 2.5%）
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CTEV vs RGEN — 直观对比
营收规模更大
CTEV
是对方的1.2倍
$197.9M
营收增速更快
RGEN
高出7.4%
6.2%
净利率更高
RGEN
高出39.4%
-32.7%
自由现金流更多
CTEV
多$18.8M
$17.6M
两年增速更快
RGEN
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $246.6M | $197.9M |
| 净利润 | $-80.6M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -3.1% | 9.0% |
| 净利率 | -32.7% | 6.7% |
| 营收同比 | 6.2% | 13.6% |
| 净利润同比 | 41.6% | 143.9% |
| 每股收益（稀释后） | $-4.88 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTEVRGEN
| Q4 25 | $246.6M | $197.9M | ||
| Q3 25 | $246.0M | $188.8M | ||
| Q2 25 | $241.6M | $182.4M | ||
| Q1 25 | $231.3M | $169.2M | ||
| Q4 24 | $232.1M | $174.1M | ||
| Q3 24 | $230.5M | $154.9M | ||
| Q2 24 | $233.5M | $154.1M | ||
| Q1 24 | $234.5M | $151.3M |
净利润CTEVRGEN
| Q4 25 | $-80.6M | $13.3M | ||
| Q3 25 | $-69.8M | $14.9M | ||
| Q2 25 | $-62.6M | $14.9M | ||
| Q1 25 | $-71.3M | $5.8M | ||
| Q4 24 | $-138.0M | $-30.3M | ||
| Q3 24 | $-391.4M | $-654.0K | ||
| Q2 24 | $-576.7M | $3.3M | ||
| Q1 24 | $-539.7M | $2.1M |
毛利率CTEVRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率CTEVRGEN
| Q4 25 | -3.1% | 9.0% | ||
| Q3 25 | 4.1% | 8.9% | ||
| Q2 25 | 6.9% | 7.6% | ||
| Q1 25 | 4.2% | 3.9% | ||
| Q4 24 | -17.8% | -17.7% | ||
| Q3 24 | -146.7% | -5.1% | ||
| Q2 24 | -224.4% | 1.0% | ||
| Q1 24 | -207.4% | 1.3% |
净利率CTEVRGEN
| Q4 25 | -32.7% | 6.7% | ||
| Q3 25 | -28.4% | 7.9% | ||
| Q2 25 | -25.9% | 8.2% | ||
| Q1 25 | -30.8% | 3.4% | ||
| Q4 24 | -59.4% | -17.4% | ||
| Q3 24 | -169.8% | -0.4% | ||
| Q2 24 | -247.0% | 2.2% | ||
| Q1 24 | -230.1% | 1.4% |
每股收益（稀释后）CTEVRGEN
| Q4 25 | $-4.88 | $0.24 | ||
| Q3 25 | $-4.23 | $0.26 | ||
| Q2 25 | $-3.81 | $0.26 | ||
| Q1 25 | $-4.38 | $0.10 | ||
| Q4 24 | $-8.49 | $-0.55 | ||
| Q3 24 | $-24.25 | $-0.01 | ||
| Q2 24 | $-35.78 | $0.06 | ||
| Q1 24 | $-33.40 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.8M | $767.6M |
| 总债务越低越好 | $4.6B | $542.2M |
| 股东权益账面价值 | $-173.9M | $2.1B |
| 总资产 | $4.9B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CTEVRGEN
| Q4 25 | $16.8M | $767.6M | ||
| Q3 25 | $39.2M | $748.7M | ||
| Q2 25 | $56.4M | $708.9M | ||
| Q1 25 | $23.1M | $697.2M | ||
| Q4 24 | $16.8M | $757.4M | ||
| Q3 24 | $86.6M | $784.0M | ||
| Q2 24 | $48.8M | $809.1M | ||
| Q1 24 | $58.7M | $780.6M |
总债务CTEVRGEN
| Q4 25 | $4.6B | $542.2M | ||
| Q3 25 | $4.5B | $537.9M | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | $525.6M | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
股东权益CTEVRGEN
| Q4 25 | $-173.9M | $2.1B | ||
| Q3 25 | $-101.8M | $2.1B | ||
| Q2 25 | $-39.9M | $2.1B | ||
| Q1 25 | $14.8M | $2.0B | ||
| Q4 24 | $84.0M | $2.0B | ||
| Q3 24 | $207.6M | $2.0B | ||
| Q2 24 | $603.4M | $2.0B | ||
| Q1 24 | $1.2B | $2.0B |
总资产CTEVRGEN
| Q4 25 | $4.9B | $2.9B | ||
| Q3 25 | $5.0B | $2.9B | ||
| Q2 25 | $5.1B | $2.9B | ||
| Q1 25 | $5.1B | $2.9B | ||
| Q4 24 | $5.2B | $2.8B | ||
| Q3 24 | $5.3B | $2.8B | ||
| Q2 24 | $5.7B | $2.9B | ||
| Q1 24 | $6.4B | $2.8B |
负债/权益比CTEVRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | 0.27× | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.3M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $36.4M | $17.6M |
| 自由现金流率自由现金流/营收 | 14.8% | 8.9% |
| 资本支出强度资本支出/营收 | 12.1% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $93.9M |
8季度趋势，按日历期对齐
经营现金流CTEVRGEN
| Q4 25 | $66.3M | $25.7M | ||
| Q3 25 | $19.9M | $48.1M | ||
| Q2 25 | $61.2M | $28.6M | ||
| Q1 25 | $-30.1M | $15.0M | ||
| Q4 24 | $-33.4M | $39.2M | ||
| Q3 24 | $72.8M | $49.3M | ||
| Q2 24 | $18.5M | $42.2M | ||
| Q1 24 | $49.7M | $44.7M |
自由现金流CTEVRGEN
| Q4 25 | $36.4M | $17.6M | ||
| Q3 25 | $-16.3M | $43.4M | ||
| Q2 25 | $36.6M | $21.5M | ||
| Q1 25 | $-68.9M | $11.4M | ||
| Q4 24 | $-63.8M | $33.6M | ||
| Q3 24 | $41.1M | $42.3M | ||
| Q2 24 | $-7.0M | $37.4M | ||
| Q1 24 | $19.2M | $36.4M |
自由现金流率CTEVRGEN
| Q4 25 | 14.8% | 8.9% | ||
| Q3 25 | -6.6% | 23.0% | ||
| Q2 25 | 15.2% | 11.8% | ||
| Q1 25 | -29.8% | 6.8% | ||
| Q4 24 | -27.5% | 19.3% | ||
| Q3 24 | 17.8% | 27.3% | ||
| Q2 24 | -3.0% | 24.3% | ||
| Q1 24 | 8.2% | 24.0% |
资本支出强度CTEVRGEN
| Q4 25 | 12.1% | 4.1% | ||
| Q3 25 | 14.7% | 2.5% | ||
| Q2 25 | 10.2% | 3.9% | ||
| Q1 25 | 16.8% | 2.1% | ||
| Q4 24 | 13.1% | 3.2% | ||
| Q3 24 | 13.8% | 4.5% | ||
| Q2 24 | 10.9% | 3.1% | ||
| Q1 24 | 13.0% | 5.5% |
现金转化率CTEVRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
